Abundant Produce receives boost from government to fast-track plant R&D
Published 28-FEB-2018 11:22 A.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Abundant Produce Limited (ASX:ABT), the only plant breeding company listed on the ASX, has today announced some good news surrounding grants and rebates.
As is custom for a small cap like ABT, it has received a Research and Development (R&D) Tax Incentive from the government — this time to the sum of ~A$630,000, which is an increase on the previous estimate of $250,000.
Further, the NSW Government’s TechVouchers program will fund a $20,000 project in collaboration with the University of NSW for the Taste of Research Programme and R&D for ABT’s Lycopene ActiveLycoTM products.
A third source of funds of over $50,000 will also be received by ABT imminently, thanks to an Export Markets Development Grant (EMDG) return, and a further $110,000 will be coming the company’s way via an Innovations Connections grants from the Australian Government which will fund a new graduate and R&D for future products.
It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
Tony Crimmins, ABT’s Group CEO commented on today’s positive news: “As a commercialisation company developing new IP for vegetable seed and varieties and lifestyle nutraceuticals, it is important that we increase shareholder value through applications for government funding. There are a number of grant facilities on a federal and state level available to ABT to reduce the impact of costs associated with development and overseas exportation of new innovative products.”
The R&D Tax Incentive provides a tax benefit to help companies like ABT offset the cost of conducting eligible research and development activities. Through the program, the government provides a return of up to 150 per cent of costs. A rebate is based on the tax rate for the company, which currently stands at 30 per cent.
Further government funds through TechVouchers and EMDG
Administered by the NSW Government, TechVouchers NSW links universities with companies to enable innovative joint research projects. ABT lodged an application to assess the feasibility of supercritical fluid extraction for our Lycopene ActiveLycoTM and received $20,000. With this fiscal support, ABT’s Abundant Natural Health division can deliver its products to the Chinese and Australian markets.
The government’s Export Markets Development Grant is an export grant provided to companies that are extending their reach on a global scale. ABT has been exporting seed to the USA, UK and the Middle East for two years and is looking to develop its export revenues further. To assist in ABT’s international success, the Federal Government’s Austrade division has refunded 50 per cent of the company’s export-associated costs — to the amount of $50,000.
An additional $110,000 in grants will assist in funding to develop lycopene extraction processes, as well as expenses relating to Chemical Engineering graduate Mitchell Austin from Sydney University.
“It is reassuring that the State and Federal Governments are recognising ABT’s innovative work through the TechVoucher and Boosting Business Innovation Programme as well as Innovation Connections, which have helped us accelerate our research and scale up both locally and internationally,” Crimmins said.
“We have built solid collaborative relationships with UNSW and The University of Sydney here in Australia and Chonnam National University in Korea allowing us to tap into some of the best high tech equipment and technical expertise globally. Essentially, it promotes innovation and collaboration between our business and the scientific research sector.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
